Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

IL-3 in the clinic

M Eder¹, G Geissler, A Ganser

¹Department of Hematology and Oncology, Hannover Medical School, Germany.

Stem Cells (Dayton, Ohio)

|January 1, 1997

Summary

This summary is machine-generated.

Human interleukin 3 (IL-3) shows promise for bone marrow failure and hematologic malignancies. Despite theoretical advantages, clinical applications are pending further research and established guidelines for IL-3 use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.

Bone marrow transplantation·2023

Same author

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Scientific reports·2023

Same author

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020

Same author

Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.

Bone marrow transplantation·2019

Same author

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Leukemia·2019

Same author

Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.

Journal of thrombosis and haemostasis : JTH·2018

Area of Science:

Hematology
Immunology
Molecular Biology

Background:

Human interleukin 3 (IL-3) was cloned in 1986 and exhibits proliferative effects on hematopoietic progenitor cells.
IL-3 has been investigated for treating bone marrow failure, hematologic malignancies, and supporting transplantation.
Unlike approved cytokines like EPO, G-CSF, and GM-CSF, no clinical use conditions for IL-3 have been established.

Purpose of the Study:

To review current knowledge on IL-3's molecular and cellular effects.
To summarize recent clinical studies involving IL-3.
To discuss future perspectives for IL-3's clinical application.

Main Methods:

Literature review of IL-3's effects.
Analysis of molecular and cellular mechanisms.

Related Experiment Videos

Summary of clinical trial outcomes.

Main Results:

IL-3 demonstrates broad effects on hematopoietic progenitor cells.
Clinical studies show potential but lack established usage protocols.
Comparison with other approved cytokines highlights IL-3's unique profile.

Conclusions:

IL-3 possesses significant theoretical advantages as an early-acting cytokine.
Further research is needed to define clinical applications and establish usage guidelines for IL-3.
Future perspectives involve optimizing IL-3's role in hematologic therapies.